A phase II clinical trial of utidelone injectable in combination with etoposide and bevacizumab for HER2 negative BCBM patients
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Depoxythilone (Primary) ; Bevacizumab; Etoposide
- Indications Brain metastases; HER2 negative breast cancer
- Focus Therapeutic Use
Most Recent Events
- 08 Apr 2024 New trial record
- 29 Mar 2024 Results (N=17), assessing excellent central nervous system (CNS) overall response rate (ORR) and CNS clinical benefit rate, presented in a Biostar media release.